BCYC

Bicycle Therapeutics Plc - ADR

Wall Street Zen cut shares of Bicycle Therapeutics from a 'hold' rating to a 'sell' rating in a research report on Saturday...

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell re...

Bicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today...

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual...

The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Morgan Stanley lowered their target price on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an "equal weight" rating for the company in a report on Wednesday...